Taiclone®
Quality Guarantee

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

S63845

Catalog No: tcsc6420

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1799633-27-4

Formula:
$C_{39}H_{37}ClF_4N_6O_6S$

Pathway:
Apoptosis

Target:
Bcl-2 Family

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (120.59 mM); H2O :

Observed Molecular Weight:
829.26

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

S63845 is a potent and selective myeloid cell leukemia 1 (**MCL1**) inhibitor; binds human MCL1 with a $\mathbf{K_d}$ of 0.19 nM.

IC50 & Target: Kd: 0.19 nM (MCL1)[1]

In Vitro: The pro-survival protein myeloid cell leukemia 1 (MCL1) is over expressed in many cancers. S63845 is a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. The activity of S63845 is next evaluated in a panel of eight AML cell lines: all lines are sensitive to S63845 (IC_{50}=4-233 nM)[1].

In Vivo: S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Intravenously injected (i.v.) S63845 exerts dose-dependent anti-tumour activity in human multiple myeloma (H929 and AMO1) xenografts in immunocompromised mice, with maximal tumour growth inhibition of 114% in the AMO1 model and 103% in the H929 model. At 25 mg/kg, S63845 induces complete regression in 7 out of 8 of the mice at 100 days after treatment in the AMO1 model[1].